---
title: "prevention of breast cancer"
slug: "prevention-of-breast-cancer"
date: "2023-02-02"
enableToc: false
tags:
- building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[Epidemiology of breast cancer]]

# prevention of breast cancer

(if high-risk: eg, FHx, LCIS, atypical hyperplasia)

* Tamoxifen (contraindic. in preg): â†“ risk contralateral breast ca as adjuvant Rx. Approved for 1Â° prevent. if â†‘ risk: â†“ invasive breast cancer, but â†‘ DVT & uterine ca.
* Raloxifene (only if post-menopausal): â†“ risk of invas breast ca, vertebral fx, & uterine ca, â†‘ risk stroke & DVT/PE (NEJM 2006;355:125); less effective than tamoxifen for prevention.
* Aromatase inhib. (post-menopausal): â†“ risk >50% (Lancet 2014;383:1041), â†‘ osteoporosis
* BRCA1/2 âŠ•: intensified surveillance vs. prophylactic bilat. mastectomy which â†“ risk ~90%; bilat. salpingo-oophorectomy â†“ risk of ovarian and breast cancer (NEJM 2016;374:454)

## Explain by ChatGPT

* The first paragraph is discussing the prevention of breast cancer, specifically in high-risk individuals. Tamoxifen is mentioned as a possible preventative measure, but it is contraindicated in pregnancy. Raloxifene is another option for post-menopausal women, but it is less effective than tamoxifen. **Aromatase inhibitors** are also mentioned as a preventative measure for post-menopausal women.

The second paragraph discusses the different risks associated with **tamoxifen and raloxifene**. Tamoxifen may decrease the risk of breast cancer, but it can also increase the **risk of DVT and uterine cancer**. **Raloxifene** may decrease the risk of breast cancer, but it can also increase the risk of **stroke** and DVT/PE.

The third paragraph discusses the different options for preventing breast cancer in women who **are BRCA1/2 positive**. Intensified surveillance is one option, but prophylactic **bilat mastectomy is more effective**, reducing the risk by 90%. Bilat **salpingo-oophorectomy** can also reduce the risk of ovarian and breast cancer.

## çª©çš„è‹±æ–‡ä¸å¤ªå¥½

ç¬¬ä¸€æ®µè¨è«–äº†ä¹³è…ºç™Œçš„é é˜²ï¼Œç‰¹åˆ¥æ˜¯é«˜å±äººç¾¤ã€‚æåˆ°ä»–è«æ˜”èŠ¬ä½œç‚ºä¸€ç¨®å¯èƒ½çš„é é˜²æªæ–½ï¼Œä½†å®ƒåœ¨æ‡·å­•æœŸé–“æ˜¯ç¦å¿Œçš„ã€‚é›·æ´›æ˜”èŠ¬æ˜¯çµ•ç¶“å¾Œå©¦å¥³çš„å¦ä¸€ç¨®é¸æ“‡ï¼Œä½†æ•ˆæœä¸å¦‚ä»–è«æ˜”èŠ¬ã€‚èŠ³é¦™åŒ–é…¶æŠ‘è£½åŠ‘ä¹Ÿè¢«æåŠä½œç‚ºçµ•ç¶“å¾Œå©¦å¥³çš„é é˜²æªæ–½ã€‚

ç¬¬äºŒæ®µè¨è«–äº†èˆ‡ä»–è«æ˜”èŠ¬å’Œé›·æ´›æ˜”èŠ¬ç›¸é—œçš„ä¸åŒé¢¨éšªã€‚ä»–è«æ˜”èŠ¬å¯é™ä½æ‚£ä¹³è…ºç™Œçš„é¢¨éšªï¼Œä½†ä¹Ÿæœƒå¢åŠ æ·±éœè„ˆè¡€æ “å’Œå­å®®ç™Œçš„é¢¨éšªã€‚é›·æ´›æ˜”èŠ¬å¯é™ä½æ‚£ä¹³è…ºç™Œçš„é¢¨éšªï¼Œä½†ä¹Ÿæœƒå¢åŠ ä¸­é¢¨å’Œ DVT/PE çš„é¢¨éšªã€‚

ç¬¬ä¸‰æ®µè¨è«–äº† BRCA1/2 é™½æ€§å¥³æ€§é é˜²ä¹³è…ºç™Œçš„ä¸åŒé¸æ“‡ã€‚å¼·åŒ–ç›£æ¸¬æ˜¯ä¸€ç¨®é¸æ“‡ï¼Œä½†é é˜²æ€§é›™å´ä¹³æˆ¿åˆ‡é™¤è¡“æ›´æœ‰æ•ˆï¼Œå¯å°‡é¢¨éšªé™ä½ 90%ã€‚é›™å´è¼¸åµç®¡åµå·¢åˆ‡é™¤è¡“é‚„å¯ä»¥é™ä½æ‚£åµå·¢ç™Œå’Œä¹³è…ºç™Œçš„é¢¨éšªã€‚
